Elina Koustoumpardi

Principal at CRA where she advises clients in mergers, Art. 101 & 102 cases as well as follow-on damages cases arising from anti-competitive conduct investigated by competition authorities in Europe, China and South Africa, in sectors ranging from pharmaceuticals, carton packaging, aviation, mining and telecoms. She provided economic advice and supporting analysis in a number of pharmaceutical mergers including Novartis/GSK, Pfizer/Hospira, Teva/Mylan and co-authored a study on the economic impacts of changing exemption provisions during patent and SPC protection of pharmaceuticals in Europe.

languages

English, Greek